Skin Cancer Melanoma Stage IV (Any T, Any N, M1)
Reviewed by Oncology Team, VICI Healthcare | Last updated: 2026-04
What Melanoma Stage IV (Any T, Any N, M1) Means
Distant metastases present: M1a (skin/subcutaneous/distant nodes), M1b (lung), M1c (other viscera or elevated LDH). Advanced disease with median OS historically 8–12 months (untreated).
Treatment Approach for Melanoma Stage IV (Any T, Any N, M1)
Systemic therapy: (1) Checkpoint inhibitor monotherapy (pembrolizumab, nivolumab) or combination ipilimumab+nivolumab (higher response rates, higher toxicity). (2) BRAF+MEK for BRAF+ disease (vemurafenib+cobimetinib, dabrafenib+trametinib). (3) PD-L1 inhibitors (atezolizumab). Surgery for oligometastatic disease (1–3 resectable lesions) may improve OS. Palliative radiotherapy for symptomatic metastases (brain, bone). Follow-up: imaging every 8–12 weeks; more frequent with systemic therapy. Clinical monitoring for immune-related adverse events.
Survival Rates and Prognosis
The 5-year survival rate for skin cancer at Melanoma Stage IV (Any T, Any N, M1) is approximately 5-year survival: 20–40% (with modern immunotherapy/targeted therapy); 5–15% (historical, pre-checkpoint inhibitor era). Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| Non-Melanoma: Low-Risk BCC/SCC | 5-year recurrence-free survival: >95% | Mohs micrographic surgery (preferred), wide local excision, curettage and… |
| Non-Melanoma: High-Risk BCC/SCC | 5-year recurrence-free survival: 50–80%; metastatic risk 5–20% for aggressive SCC variants | Mohs micrographic surgery or wide local excision with adequate margins (5–10… |
| Melanoma Stage I (T1–2, N0, M0) | 5-year survival: 85–95% (stage IA); 70–80% (stage IB) | Wide local excision (10–20 mm margins depending on thickness and anatomic… |
| Melanoma Stage II (T3–4, N0, M0) | 5-year survival: 60–75% (stage IIA–IIB); 50–60% (stage IIC) | Wide local excision (10–20 mm margins). SLNB strongly recommended. Adjuvant… |
| Melanoma Stage III (T1–4, N1–3, M0) | 5-year survival: 50–70% (stage IIIA); 40–50% (stage IIIB); 25–40% (stage IIIC) | Complete lymph node dissection (CLND) historically standard; trend toward… |
| Merkel Cell Carcinoma (Stage I–IV) | 5-year survival: 70–80% (stage I); 50% (stage II–III); 25% (stage IV) | Stage I–II: wide local excision (1–2 cm margins) + SLNB + adjuvant radiation…. |
Skin Cancer Treatment in Top Cities
Skin Cancer in Gurgaon
Skin Cancer in Noida
Skin Cancer in Mumbai
Skin Cancer in Bangalore
Skin Cancer in Hyderabad
Skin Cancer in Chennai
Skin Cancer in Kolkata
Diagnosed with Melanoma Stage IV (Any T, Any N, M1) Skin Cancer?
Our specialists can review your reports and create a personalised treatment plan.